Novartis Bolts on Spinifex to Bolster its Neuroscience Franchise
By Heather Cartwright & Hardik Mewada
Pharma Deals Review: Vol 2015 Issue 8 (Table of Contents)
Published: 6 Aug-2015
DOI: 10.3833/pdr.v2015.i8.2114 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In a somewhat surprise foray into the field of neuropathic pain management, Novartis has agreed to acquire privately held Spinifex Pharmaceuticals for US$200 M upfront plus up to US$500 M contingent on the achievement of certain milestones...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS